Daily Roundup

Gold miner Ramelius Resources wrapped up the September quarter with solid production numbers, posting 48,839 ounces of gold at an all-in sustaining cost of A$2,656 per ounce. Weather interruptions during the period led to increased stockpiles, but the company still managed to generate A$186 million in operating cash flow. More importantly, Ramelius completed the sale of its Edna May operation for A$300 million—a strategic move that saw the company pocket A$210 million in cash and A$90 million in Forrestania shares. The company's balance sheet is looking healthier too, with cash and gold reserves now sitting at A$768 million. Looking ahead, Ramelius remains on track to hit its full-year guidance of 205,000 to 225,000 ounces at an AISC of A$2,150 to A$2,350 per ounce, and the company is systematically derisking its business plan with ambitions to become a 600,000 ounce producer by FY30.

Data analytics company Pureprofile is firing on all cylinders. The firm reported record quarterly revenue of $18.3 million in Q1 FY27, up 14 percent compared to the same period last year. Even more impressive was the 27 percent jump in EBITDA to $2.4 million, which outpaced revenue growth and pushed the EBITDA margin to 13 percent. The real standout was platform revenue, which more than doubled to $8.8 million—now representing 48 percent of total revenue. ANZ operations grew 21 percent to $9.6 million, while the Rest of World segment increased 7 percent to $8.7 million. Pureprofile now works with over 1,000 clients globally and has extended its A$2.5 million Commonwealth Bank facility through November 2029 on improved terms. For the full year, the company is guiding for revenue between $72 million and $75 million with an EBITDA margin of 11 to 12 percent.

Medical technology company Artrya is making meaningful strides in the U.S. market. The Australian firm signed a five-year commercial agreement with Huntsville Hospital Health System, its largest customer to date. Huntsville also became the first participant in Artrya's SAPPHIRE study to transition to full commercial use. Meanwhile, the implementation of a pre-authorization workflow at Tanner Health has driven a material increase in utilization of the company's Salix® Coronary Plaque module. Artrya also bolstered its governance by strengthening its Board and executive leadership team, and the company was recently included in the S&P/ASX 300 Index—a vote of confidence from the market.

Biotech company Invex Therapeutics is expanding its pipeline through acquisition. Invex has entered into a binding agreement to acquire 100 percent of Rekover Therapeutics, a New Zealand biotech firm working on repurposing nalfurafine for demyelinating diseases. The deal will be settled with 45 million shares and 91.25 million performance rights, with no cash changing hands upfront. To fund the transaction and support its REVIVE Study, Invex is planning a capital raise of $10 million through a placement of shares at $0.08 each. A$1.25 million in commitments are already locked in, with the remainder subject to shareholder approval.

Mach7 Technologies has hit a major milestone—the company just posted its first positive operating cash flow in its history. For Q1 FY27, Mach7 generated A$0.3 million in positive operating cash flow, marking the fourth consecutive quarter in the black. The imaging software company's Annual Recurring Revenue run rate climbed to A$23.5 million, up 8.5 percent in constant currency compared to the same quarter last year. Receipts jumped 58 percent compared to the prior corresponding period, reflecting customer growth and improved cash collection. Mach7 is maintaining a fortress balance sheet with A$19.3 million in cash and zero debt. The company is also gearing up for a major product reveal at RSNA 2026, where it will showcase its next-generation Flamingo architecture—a modular platform designed to expand the company's addressable market and drive future growth.